Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival

Annals of Oncology

Volumn 20, Issue 9, 2009, Pages 1589-1595

  Jarnagin, W R ^a   Schwartz, L H ^a   Gultekin, D H ^a   Gonen M ^a   Haviland, D ^a   Shia, J ^a   D'Angelica, M ^a   Fong, Y ^a   DeMatteo, R ^a   Tse, A ^a   Blumgart, L H ^a   Kemeny, N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

DCE MRI; HAI FUDR; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma

Indexed keywords

DEXAMETHASONE; FLOXURIDINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; EXTRACELLULAR SPACE; EXTRAVASCULAR SPACE; FEMALE; FOLLOW UP; HUMAN; INOPERABLE CANCER; INTRAVASCULAR SPACE; LIVER CANCER; LIVER CELL CARCINOMA; MALE; MICROVASCULATURE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHOLANGIOCARCINOMA; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 69849103783     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp029     Document Type: Article

References (41)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357.
3. Endo I, Gonen M, Yopp AC et al. Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248(1): 1-13.
4. Fong Y, Sun RL, Jarnagin W et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999; 229: 790-799.
5. Cheng BQ, Jia CQ, Liu CT et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: A randomized controlled trial. JAMA 2008; 299: 1669-1677.
6. Wood TF, Rose DM, Chung M et al. Radiofrequency ablation of 231 unresectable hepatic tumors: Indications, limitations, and complications. Ann Surg Oncol 2000; 7: 593-600.
7. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359: 1734-1739.
8. Knox JJ, Hedley D, Oza A et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. J Clin Oncol 2005; 23: 2332-2338.
9. Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24: 3069-3074.
10. Andre T, Tournigand C, Rosmorduc O et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: A GERCOR study. Ann Oncol 2004; 15: 1339-1343.
11. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293-4300.
12. Llovet JM. Sorafenib improved survival in advanced hepatocellular carcinoma (HCC): Results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I 2007; 25 (Suppl): 18S LBA1 2007.
13. Ensminger WD, Rosowsky A, Raso V et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2#-deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38: 3784-3792.
14. Kemeny N, Huang Y, Cohen AM et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048.
15. Kemeny N, Jarnagin W, Paty P et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888-4896.
16. Atiq OT, Kemeny N, Niedzwiecki D et al. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. Cancer 1992; 69: 920-924.
17. Clavien PA, Selzner N, Morse M et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002; 131: 433-442.
18. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006; 24: 3293-3298.
19. Devries AF, Griebel J, Kremser C et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 2001; 61: 2513-2516.
20. Hoskin PJ, Saunders MI, Goodchild K et al. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol 1999; 72: 1093-1098.
21. Evelhoch J, Garwood M, Vigneron D et al. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: Workshop report. Cancer Res 2005; 65: 7041-7044.
22. Evelhoch JL, LoRusso PM, He Z et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004; 10: 3650-3657.
23. Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
24. van Laarhoven HW, Klomp DW, Rijpkema M et al. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 2007; 20: 128-140.
25. Allen PJ, Nissan A, Picon AI et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: An institutional experience of 544 consecutive cases. J Am Coll Surg 2005; 201: 57-65.
26. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
27. Kety SS. The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol Rev 1951; 3: 1-41.
28. Weinmann H, Laniado M, Mützel W. Pharmacokinetics of GdDTPA/ dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984; 16: 167-172.
29. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991; 17: 357-367.
30. Wang Y, Huang W, Panicek DM et al. Feasibility of using limited-populationbased arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI data. Magn Reson Med 2008; 59: 1183-1189.
31. Tofts PS, Brix G, Buckley DL et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
32. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002; 15: 154-163.
33. Jackson A, O'Connor JP, Parker GJ et al. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007; 13: 3449-3459.
34. Mills SJ, Patankar TA, Haroon HA et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006; 27: 853-858.
35. Kemeny N, Cohen A, Seiter K et al. Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993; 11: 330-335.
36. Ikai I, Arii S, Okazaki M et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691.
37. Galbraith SM, Lodge MA, Taylor NJ et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002; 15: 132-142.
38. Basaki Y, Chikahisa L, Aoyagi K et al. Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 2001; 4: 163-173.
39. Ooyama A, Oka T, Zhao HY et al. Anti-angiogenic effect of 5-fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett 2008; 267(1): 26-36.
40. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: From black and white to shades of grey. Nat Rev Cancer 2006; 6: 409-414.
41. O'Dwyer P, Rosen M. Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 2005; 23 (Suppl): 16S Part I of II 3005. 2005.